Evotec AG | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
25,433.00
6,978.00
16,516.00
26,839.00
23,999.00
84,056
Depreciation, Depletion & Amortization
9,165.00
8,536.00
11,941.00
11,893.00
20,766.00
31,293
Other Funds
278.00
1,813.00
551.00
765.00
-
4,919
Funds from Operations
13,367.00
15,080.00
12,159.00
48,125.00
46,509.00
84,313
Changes in Working Capital
6,710.00
18,877.00
3,492.00
19,235.00
35,681.00
71,927
Net Operating Cash Flow
6,657.00
3,797.00
15,651.00
67,360.00
10,828.00
156,240
Capital Expenditures
5,190.00
5,282.00
11,496.00
10,149.00
17,587.00
Sale of Fixed Assets & Businesses
583.00
1,069.00
-
-
691.00
Purchase/Sale of Investments
27,025.00
7,188.00
11,926.00
4,176.00
252,137.00
Net Investing Cash Flow
31,513.00
2,975.00
23,422.00
5,973.00
269,033.00
Issuance/Reduction of Debt, Net
184.00
4,251.00
1,066.00
19,724.00
148,368.00
Net Financing Cash Flow
31,936.00
3,096.00
2,486.00
19,671.00
240,724.00
Net Change in Cash
6,579.00
3,066.00
4,213.00
39,443.00
16,923.00
Free Cash Flow
1,497.00
9,079.00
4,487.00
57,357.00
6,737.00
Deferred Taxes & Investment Tax Credit
1,486.00
39.00
6,666.00
1,750.00
6,144.00
26,117
Other Sources
119.00
-
-
-
-
Change in Capital Stock
32,398.00
658.00
1,971.00
818.00
92,356.00
Exchange Rate Effect
501.00
792.00
1,072.00
2,273.00
558.00

About Evotec

View Profile
Address
Manfred Eigen Campus
Hamburg Hamburg 22419
Germany
Employees -
Website http://evotec.com
Updated 07/08/2019
Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the EVT Execute and EVT Innovate segments. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties.